New insights on the impact of tapering GCs or immunosuppressive therapy on damage accrual after achieving LLDAS and complete remission SLE
Systemic lupus erythematosus (SLE) is a lifelong disease with a median onset age of 15-44 years.1 As continued treatment with glucocorticoids (GCs) and immunosuppressive therapies can contribute to damage accrual, tapering of treatment is inevitable during the course of the disease.1 However, this c